CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its Board of Directors has appointed Steve Hoerter, current Executive Chairman of the Board, as its new Chairman and Chief Executive Officer. Mr. Hoerter succeeds Kent Hawryluk, who will step down as President, Chief Executive Officer and a member of the Board of Directors. In addition, the Board has appointed John Smither, current Interim Chief Financial Officer, as the Company's new Chief Financial Officer. All leadership changes are effective immediately.

globenewswire.com - 2026-07-13 16:15:00

I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables longer-acting, less frequent dosing, addressing key safety and compliance issues in hypoparathyroidism and obesity. Canvuparatide's Phase 2 data show strong efficacy and patient benefit, but Phase 3 must address PK variability and long-term calcium control risks.

seekingalpha.com - 2026-07-06 08:38:04

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript

seekingalpha.com - 2026-06-12 14:32:09

MBX Biosciences Inc. (NASDAQ:MBX) on Thursday reported full results from its 12-week Avail Phase 2 trial and new one-year data from an ongoing open-label extension study of once-weekly canvuparatide in adults with chronic hypoparathyroidism.

benzinga.com - 2026-06-12 10:43:54

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial

globenewswire.com - 2026-06-12 07:00:00

CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will host an investor webcast and conference call at 8:00 am ET on Friday, June 12, 2026 to discuss presentations for once-weekly canvuparatide at the upcoming Endocrine Society's Annual Meeting (ENDO 2026) in Chicago.

globenewswire.com - 2026-06-01 08:00:00

MBX Biosciences, a clinical-stage biotech developing peptide therapies, reported a notable insider sale after a year of rapid stock gains.

fool.com - 2026-05-27 15:18:24

CARMEL, Ind. and BURLINGTON, Mass.

globenewswire.com - 2026-05-26 08:00:00

Microbix Biosystems Inc. (MBX:CA) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-14 14:31:00

MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio Transcript

seekingalpha.com - 2026-05-11 20:10:44

MBX Biosciences NASDAQ: MBX used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key development milestones across its endocrine and metabolic disease pipeline.

marketbeat.com - 2026-05-11 15:09:21

Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo)

globenewswire.com - 2026-05-11 07:00:00

Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026 Appointment of Mark Soued as Chief Commercial Officer adds launch and commercialization expertise Company to host Obesity Day on May 11 th featuring initial blinded data from ongoing MBX 4291 Phase 1 trial and update on expanding obesity portfolio $440.0 million in cash and investments expected to support operations into 2029 CARMEL, Ind. and BURLINGTON, Mass.

globenewswire.com - 2026-05-07 08:00:00

Results Release and Webinar Discussion on Morning of May 14, 2026 MISSISSAUGA, ON / ACCESS Newswire / May 7, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its second quarter of fiscal 2026 ended March 31, 2026 ("Q2 2026") prior to the start of trading on May 14, 2026. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q2 2026 results with its CEO, CFO, and COO.

accessnewswire.com - 2026-05-07 07:00:00

CARMEL, Ind. and BURLINGTON, Mass.

globenewswire.com - 2026-05-07 07:00:00

These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.

fool.com - 2026-05-05 08:45:00

MISSISSAUGA, ON / ACCESS Newswire / April 27, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that one of its clients is presenting results of Microbix made quality assessment products ("QAPs™") that help enable full-process quality management of molecular assays to detect human papillomavirus ("HPV") at 2026 PASCV. 2026 PASCV is the annual meeting and principal gathering of the Pan American Society for Clinical Virology, taking place in Clearwater Beach, Florida April 29 to May 1, 2026.

accessnewswire.com - 2026-04-27 07:00:00

CARMEL, Ind. and BURLINGTON, Mass.

globenewswire.com - 2026-04-23 08:00:00

Releasing Episodes of Season Two of "Diagnostics: Beyond the Lab" Podcast MISSISSAUGA, ON / ACCESS Newswire / April 20, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces it is releasing three episodes of the second season of its podcast titled "Diagnostics: Beyond the Lab." This Microbix podcast series engages with third-party experts to discuss opportunities and challenges facing the diagnostics industry - to inform policy-makers, medical or scientific professionals, and patients.

accessnewswire.com - 2026-04-20 07:00:00

MISSISSAUGA, ON / ACCESS Newswire / April 16, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the 2026 Bloom Burton & Co. Healthcare Investor Conference (the "Conference") taking place at the Metro Toronto Convention Centre, North Building, on April 21 and 22, 2026. The Conference provides Microbix the opportunity to build connections with Canadian, U.S., and international investors focused on the latest developments in the Canadian healthcare and life sciences sector.

accessnewswire.com - 2026-04-16 07:00:00